Conferences
ASCO GU 2025: Clinically Advanced Urothelial Bladder Cancer in Young Onset Bladder Cancer (YOUC) Patients: A Genomic Landscape Study
February 15, 2025
ASCO GU 2025: A Phase 2 Trial of Risk Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for Muscle-Invasive Bladder Cancer (RETAIN-2)
February 15, 2025
ASCO GU 2025: Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-Guérin
February 15, 2025
ASCO GU 2025: Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With UGN-102: Results of the Phase 3 ATLAS and ENVISION Studies
February 15, 2025
ASCO GU 2025: Discussant: Adjuvant Immunotherapy in High Risk Muscle Invasive Bladder Cancer
February 15, 2025
ASCO GU 2025: Optyx Study: Clinical Characteristics and Preferences for Initiating Relugolix in a Cohort of US Patients in Real-World Care Settings
February 15, 2025